Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center
Movement Disorders Clinical Practice · 2024
DOI: 10.1002/mdc3.14130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Mena Farag und 10 weiteren Autor:innen. Beteiligte Einrichtung: Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Gastrostomy, Huntington Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Background
Clinically assisted nutrition and hydration via percutaneous endoscopic gastrostomy (PEG) is a therapeutic option to ameliorate the difficulties associated with enhanced catabolism, weight loss, and dysphagia in Huntington's disease (HD).
Objectives
The objective is to provide insights into demographics, staging (Shoulson‐Fahn), complications, weight trajectories, and survival rates in people with HD (pwHD) who underwent PEG.
Methods
This retrospective study included 705 consecutive pwHD who attended our HD clinic between July 2006 and March 2024, of whom 52 underwent PEG. A control group (n = 52), comprising pwHD without PEG, were closely matched for sex, stage, age, CAG length, and disease burden score at PEG. The study was registered as a service evaluation at the National Hospital for Neurology and Neurosurgery.
Results
PEG prevalence was 15.0% (n = 52/347) among manifest pwHD: 4.8% (n = 3/62) for Stage 3; 33.3% (n = 16/48) for stage 4; and 44.1% (n = 30/68) for stage 5. Commonest indications were dysphagia, weight loss, and inadequate oral intake. Complications included chest infection, tube dislodgement, and peristomal and skin infections. Modeling of weight trajectories after PEG found no difference between PEG and non‐PEG groups. Mortality rate was 34.6% (n = 18/52) in the PEG and 36.5% (n = 19/52) in the non‐PEG groups ( P = 0.84). Treatment duration (until study endpoint or death) was 3.48 years (interquartile range = 1.71–6.02; range = 0.23–18.8), with 65.4% (n = 34/52) alive at the study endpoint.
Conclusion
PEG in pwHD at‐risk for weight loss may help slow weight loss. Prospective studies are required to strengthen PEG decision‐making in pwHD. PEG survival was much longer than other dementias, highlighting the need to consider PEG independently in pwHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
- The National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, London, United Kingdom.
- Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
ORCID-Profile: Mena Farag, Sarah J Tabrizi
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Farag, M., Coleman, A., Knights, H., Murphy, M. J., Rajagopal, S., Touzé, A., Shoai, M., Hearst, C., Salanio, D. M., Wild, E. J., & Tabrizi, S. J. (2024). Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14130
Vancouver
Farag M, Coleman A, Knights H, Murphy MJ, Rajagopal S, Touzé A, et al. Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14130
BibTeX
@article{Farag2024,
author = {Farag, Mena and Coleman, Annabelle and Knights, Harry and Murphy, Michael J and Rajagopal, Sangeerthana and Touzé, Alexiane and Shoai, Maryam and Hearst, Cara and Salanio, Desiree M and Wild, Edward J and Tabrizi, Sarah J},
title = {Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center},
journal = {Movement Disorders Clinical Practice},
year = {2024},
doi = {10.1002/mdc3.14130}
}
EUVIMED